UBS raised the firm’s price target on Iqvia to $300 from $295 and keeps a Buy rating on the shares. The company’s healthy backlog and tech/data-forward offering should enable market share gains, but Q2’s Technology & Analytical Solutions-driven beat and slightly softer than forecast R&D Solutions have mixed implications, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV: